Disruption and maturity: the future directions for biologics in healthcare
pharmaphorum
JUNE 20, 2017
A digital debate analysing the future for biologics in the UK and the factor affecting market access in this territory. Our expert panel will cover a number of key topics including: •Are the savings offered by biosimilars being used to innovate and take advantage of the exciting new biologic technologies or just filling in the NHS potholes? •Will the industry continue to invest in cutting-edge research if the UK is not prepared to fund access to it •In a post-Brexit world how can the UK continue
52 
Let's personalize your content